|
Orthologous residues
|
|
p73 (human): S388‑p, p73 iso2 (human): S388‑p, p73 (mouse): S380‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, western blotting
|
|
Disease tissue studied:
lung cancer, small-cell lung cancer
|
|
Relevant cell lines - cell types - tissues:
H82
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKCB iso2 (human)
|
transfection of wild-type enzyme, transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
|
|
|
KINASE
|
PKCA (human)
|
transfection of wild-type enzyme, transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
siRNA
|
|
|
|
decrease
|
|
|
PKC412
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation
|
|
Effect of modification (process):
cell cycle regulation, transcription, altered
|
|
Comments:
regulates genes involved in cell cycle progression
|
